- The 8 States Most Likely to Legalize Marijuana Next
- Dow 18,000: Why This Market Rally May Never Happen Again
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
- BlackBerry Classic Review: A Bold Update for CrackBerry Fans
Markets continued to take out new highs, with the Dow closing over 18,000 for the first time ever.
Jared Woodard, Senior Equity Derivatives Strategist and TheStreet's Jill Malandrino recap a choppy trading week as volatility made a huge comeback in the market.
Commodities were once again in the spotlight as oil continues to deal with the supply glut and markets reacted from the FOMC rate decision and commentary.
Juno Therapeutics CEO Hans Bishop tells TheStreet Juno is focused on the better treatment of patients with cancer.
The IPO market was hot in 2014, particularly for Nasdaq listings as 61% of all U.S. and 60% of international new issues debuted on the Nasdaq.
Marchay Co-Founder, Karl Backlund, tells TheStreet the company is a private travel community for the executive traveler, focusing on the luxury market.
HealthyWage.com CEO, Jimmy Fleming, says users state how much weight they want to lose and in what timeframe, and HealthyWage pays a proprietary payout, if you achieve the weight loss.
Gold prices have been relatively stable heading into the FOMC rate decision on Wednesday, up until the overnight session into Tuesday.
Crude mas moved lower by over $10 per barrel over the past five trading sessions.
4.5 million patients worldwide rely on supplemental oxygen therapy to treat their medical conditions.